Kinase mutations in human disease: interpreting genotype–phenotype relationships

Lahiry, Piya, Torkamani, Ali, Schork, Nicholas J., Hegele, Robert A.·2010·Nature Reviews Genetics
DOI 10.1038/nrg2707

Cited by (429)

Items 401–429 of 429

  1. In silico design of natural-based structures as drug candidates to inhibit ROS1 protein
    Mohammadjavad Maleki, Alireza Fattahi · 2025 · Scientific Reports
  2. Paradoxical non-catalytic kinase functions are driven by inhibitor-induced displacement of autoinhibitory domains
    Viviane Reber, Sabrina Keller, Stefanie A. Loosli, Yumi Arima, Tatjana Kleele, Paola Picotti, Matthias Gstaiger · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
  3. Additional file 1 of Multi-omics analysis identifies drivers of protein phosphorylation
    Zhang, Tian, Gregory R. Keele, Gyuricza, Isabela Gerdes, Matthew J. Vincent, Catherine Brunton, Timothy A. Bell, Pablo Hock, Ginger D. Shaw, Steven C. Munger, de Villena, Fernando Pardo-Manuel et al. · 2023 · Figshare
  4. Additional file 7 of Multi-omics analysis identifies drivers of protein phosphorylation
    Zhang, Tian, Gregory R. Keele, Gyuricza, Isabela Gerdes, Matthew J. Vincent, Catherine Brunton, Timothy A. Bell, Pablo Hock, Ginger D. Shaw, Steven C. Munger, de Villena, Fernando Pardo-Manuel et al. · 2023 · Figshare
  5. Investigating stability landscape of Aurora kinase B probed by guanidinium chloride-induced unfolding
    Gulam Mustafa Hasan, Yuxin Xie, Safikur Rahman, Saba Noor, Thiyagarajan Ramesh, Faez Iqbal Khan, Md. Imtaiyaz Hassan · 2026 · International Journal of Biological Macromolecules
  6. pKAKA: a protein language model for prioritizing kinase-disrupting variants in diseases.
    Jun-Teng Li, Hao-Yang Cheng, Zhuoran Liang, Jiamin Hu, Yi-Ting Chu, Ruoxi Cai, Bijin Cao, Ying Jin, Yutao Xie, Huai-Qiang Ju et al. · 2026 · Journal of genetics and genomics = Yi chuan xue bao
  7. Polypharmacology is an enduring and nearly universal property of kinase inhibitors
    Caitlin E. Mills, Clemens B. Hug, Karuna Anna Sajeevan, Nicholas Clark, Chiara Victor, Mirra Chung, Sameer Rawat, Hope D’Erasmo, Mariana Pereira Moraes, Bree B. Aldridge et al. · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
  8. Anti-breast cancer activity of 6-bromo 2,3-disubstituted quinazolinone analogues as active dual EGFR and VEGFR2 inhibitors
    Safar M. Alqahtani, Yassine Riadi, Obaid Afzal · 2026 · Arabian Journal of Chemistry
  9. Valorisation de substances naturelles marines de Nouvelle-Calédonie d'intérêt en traitement anticancéreux
    Sofia-Elena Motuhi · 2016 · theses.fr (ABES)
  10. Méthodologies de synthèses d'hétérocycles bicycliques (6-5) et (5-5). Application à la conception d'inhibiteurs de kinases impliquées en oncologie et dans les maladies du système nerveux central.
    Matthieu Place · 2017 · theses.fr (ABES)
  11. Du génotype au phénotype : Analyse comparée de mutations du gène de déficience intellectuelle PAK3
    Kévin Duarte · 2019 · theses.fr (ABES)
  12. Conception rationnelle, synthèse et évaluation biologique d'inhibiteurs de la voie de signalisation LIMK/ROCK
    A. Champiré · 2018
  13. Development of small molecules modulating the activity of the nucleoside kinase dCK
    Khaoula Ben Yaala · 2021 · theses.fr (ABES)
  14. Kinome profiling allows examination and prediction of kinase inhibitor cardiotoxicity
    Jimmy S. Tabet, Chinmaya U. Joisa, Brian C. Jensen, Shawn M. Gomez · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
  15. Introduction to kinases and their functions
    Wenjian Zhu, Xiaoyun Lu · 2026 · Elsevier eBooks
  16. Challenges in kinase inhibitors discovery
    Jibo Kang, Xiaoyun Lu · 2026 · Elsevier eBooks
  17. A kinase-related gene signature predicts prognosis and therapeutic response in head and neck squamous cell carcinoma
    Yang Zhang, Pin Lv, Guangrui Cao, Na Qi, Miao Yu, Yaping Wu · 2026 · Oral Oncology
  18. Targeting kinases in neurodegenerative diseases and cancer: Structural insights and therapeutic strategies
    Anas Shamsi, Saleha Anwar, Khuzin Dinislam · 2026 · Advances in protein chemistry and structural biology
  19. STK38/L promote tissue growth and cancer by inhibiting the Hippo pathway
    Jeongmin An, Zhen Huang, Amrutha Kizhedathu, Tian Lan, Tzuling Lin, Hyejin Joo, Eshan Malinda Thilakaratne, Yuhan Liu, Yun Yi Xu, Bing Yang et al. · 2026 · Genes & Development
  20. Paradoxical non-catalytic kinase functions are driven by inhibitor-induced displacement of autoinhibitory domains
    Viviane Reber, Sabrina Keller, Stefanie A. Loosli, Yumi Arima, Tatjana Kleele, Paola Picotti, Matthias Gstaiger · 2026 · Molecular Systems Biology
  21. Scop3P in 2026: an expanded proteomics-informed resource contextualizing phosphorylation sites through sequence, structure, mutation, and experimental provenance
    Pathmanaban Ramasamy, Natalia Tichshenko, Adrián Díaz, Kevin Velghe, Enrico Massignani, Wim Vranken, Lennart Martens · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
  22. Unveiling Large-Scale Kinase-Centric Protein–Protein Interactions through a Knowledge-Informed Workflow
    J B Hu, Shimian Li, Y J Xue, Yijie Xia, S Liu, Yi Qin Gao · 2026 · Journal of Chemical Information and Modeling
  23. Carbazole derivatives as privileged scaffolds for kinase inhibition: advances in design, therapeutic applications and mechanisms
    Saba Munawar, Muhammad Jawwad Saif, Samreen Gul Khan, Ameer Fawad Zahoor, Bushra Parveen, Fareeha Hafeez, Musa A. Said · 2026 · Future Medicinal Chemistry
  24. BindingDB Entry 50018286: Molecular hybrids: A five-year survey on structures of multiple targeted hybrids of protein kinase inhibitors for cancer therapy.
    BindingDB · 2024 · UC San Diego
  25. BindingDB Entry 50002905: Exploiting polypharmacology for improving therapeutic outcome of kinase inhibitors (KIs): An update of recent medicinal chemistry efforts.
    BindingDB · 2020 · UC San Diego
  26. BindingDB Entry 50017048: Small Molecule Kinase Inhibitor Drugs (1995-2021): Medical Indication, Pharmacology, and Synthesis.
    BindingDB · 2023 · UC San Diego
  27. BindingDB Entry 50016594: Kinase Inhibitors as Underexplored Antiviral Agents.
    BindingDB · 2023 · UC San Diego
  28. BindingDB Entry 50018847: Silmitasertib (CX-4945), a Clinically Used CK2-Kinase Inhibitor with Additional Effects on GSK3β and DYRK1A Kinases: A Structural Perspective.
    BindingDB · 2024 · UC San Diego
  29. Redox Regulation of PTPs in Metabolism: Focus on Assays
    Yang Xu, Benjamin G. Neel · 2013 · Springer eBooks